Fixed-combination of rosuvastatin with ezetimibe in the treatment of secondary prevention patient


Authors: Martina Vaclová;  Michal Vrablík
Authors‘ workplace: Centrum preventivní kardiologie, III. Interní klinika VFN a 1. LF UK v Praze
Published in: AtheroRev 2018; 3(3): 197-200
Category:

Overview

The case report documents a secondary prevention patients referred to the Centre of preventive cardiology of the GUH in Prague due to persistent elevation of LDL-C levels despite maximum intensity treatment.The case report documents a secondary prevention patients referred to the Centre of preventive cardiology of the GUH in Prague due to persistent elevation of LDL-C levels despite maximum intensity treatment.

Key words:

ezetimibe, LDL-C, PCSK9 inhibitors, secondary prevention, statin, total cholesterol, treatment goals

Received: 14. 9. 2018

Accepted: 1. 10. 2018


Sources
  1. Vrablik M, Freiberger T, Bláha V et al. [Pracovní skupina České společnosti pro aterosklerózu]. Souhrn konsenzu panelu expertů European Atherosclerosis Society k otázce diagnostiky a klinickému vedení nemocných s familiární hypercholesterolemií. Hypertenze a KV prevence 2015; 4(2): 44–48.
  2. Tichy L, Fajkusova L, Zapletalova L et al. Molecular Genetic Back­ground of an Autosomal Dominant Hypercholesterolemia in the Czech Republic. Physiol Res 2017; 66(Suppl 1): S47-S54.
  3. Vrablik M, Piťha J, Bláha V et al. Stanovisko výboru České společnosti pro aterosklerózu k doporučením ESC/EAS pro diagnostiku a léčbu dys­lipidemií z roku 2016. AtheroRev 2017; 2(3): 185–193.
  4. Chapman RH, Benner JS, Petrilla AA et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165(10): 1147– 1152. Dostupné z DOI: <http://dx.doi.org/10.1001/archinte.165.10.1147>.
  5. Varbo A, Benn M, Tybjærg-Hansen A et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013; 61(4): 427–436. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2012.08.1026>.
  6. Vrablik M. Farmakoterapie dyslipidemie. 2. vyd. Maxdorf: Praha 2016. ISBN 978–80–7345–503–3.
  7. Stone NJ, Robinson JG, Lichtenstein AH et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun; 129(25 Suppl 2): S1-S45. Dostupné z DOI: <http://dx.doi.org/10.1161/01.cir.0000437738.63853.7a>. Erratum in Correction. [Circulation. 2015]Circulation 2014; 129(25 Suppl 2): S46-S48.
  8. Vrablík M, Šatný M, Laštůvka J. Ezetimib v léčbě diabetické dyslipid­emie. DMEV 2018; 21(2): 71–74.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adults
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account